Nymox Pharmaceutical (NYMX +0.6%) ticks up after saying that Phase 3 immunogenicity trials of...

|About: Nymox Pharmaceutical Corpor... (NYMX)|By:, SA News Editor

Nymox Pharmaceutical (NYMX +0.6%) ticks up after saying that Phase 3 immunogenicity trials of its lead drug candidate NX-1207 have not shown any evidence of eliciting an immune reaction in men treated with intraprostatic injections of the drug.